AAKAAR AAKAAR Q2 FY27 results (Jul–Sep 2026) and concall
Aakaar Medical Technologies achieved a decisive operational turnaround in H1 FY27, generating revenue from operations of ₹43.72 crores (up 72.64% YoY) and net profit of ₹3.54 crores compared to a loss of ₹0.80 crores in H1 FY26. Growth was propelled by strong adoption of imported aesthetic brands, ongoing traction in own brands (₹14.90 crores), and the rollout of the Xelix DODO clinic platform with 70+ onboarded doctors. However, profitability and liquidity were pressured by gross margin compression to 51.39% (down from 57.88% in March 2026), elevated marketing expenses of ₹3.40 crores, and de
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q4 FY25 | Q2 FY26 | Q4 FY26 | Q2 FY27 |
|---|---|---|---|---|
| Revenue | 34 | 25 | 42 | 44 |
| EBITDA | 8 | 0 | 10 | 5 |
| Net profit | 6 | -1 | 7 | 4 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
